NEW YORK – Digital pathology firms Corista and Qritive announced on Sunday that they have partnered to integrate their digital pathology solutions.
Under the partnership, Corista's DP3 image management platform and Qritive's artificial intelligence-based modules will be combined into one solution. That solution will enable computational models to be used to screen for prostate and colon cancers, quantify immunohistochemistry markers, and detect lymph node metastasis, the companies said in a statement. It will also allow for pre-reviewed AI analysis of digital pathology images using any whole-slide scanner and laboratory information system.
"Corista's image management system combined with the assistive power of Qritive's AI modules is the ideal workbench for pathologists to conduct diagnostics with ease, consistency, and precision," Qritive CEO and Cofounder Aneesh Sathe said in a statement.
The partnership "will advance the use of artificial intelligence applications to support the growing demands on pathologists to keep up with the pace of their workloads, and the challenges of cancer diagnosis," added Liz Wingard, Corista's CEO and cofounder.
Financial and other terms of the deal were not disclosed.